Keywords
Child
Adolescent
Obesity
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To verify the scientific evidence of the main treatments to reduce insulin resistance (IR) in obese or overweight children and adolescents. Methods: A systematic review was performed based on the search for articles published between January 1, 2000, and June 1, 2021, in PubMed, MEDLINE, Cochrane Library, Embase, and LILACS databases, using the following descriptors: insulin resistance, child, adolescent, treatment, obesity, overweight, and adults. A pair of reviewers analyzed the articles, and the quality's methodological articles were evaluated based on the verification items of the CONSORT strategy. Results: 1156 articles were found, remaining 20 studies, after analysis and submission to the inclusion and exclusion criteria. Of these, 10 compared the use of metformin to placebo, 2 evaluated the use of omega-3, 1 studied the use of rosiglitazone, and 7 verified the effectiveness of lifestyle changes. Final considerations: Metformin presents different results in the literature, unlike lifestyle change, especially physical activity, which reduced IR in most analyzed studies. The use of omega-3 is suggestive of a good response, and rosiglitazone was withdrawn from the Brazilian and European markets even though it reduced the IR.
References
ABESO. Diretrizes Brasileiras de Obesidade 2016. 4 ed. São Paulo: Companygraf, 2016; 188p.
ADEYEMO MA, et al. Effects of metformin on energy intake and satiety in obese children. Diabetes, obesity & metabolism, 2015; 17(4): 363-370.
ALBURQUERQUE LC, et al. Alterações metabólicas na obesidade infantil e fatores de risco cardiovascular: uma revisão integrativa. Revista Eletrônica Acervo Científico, 2019; 7: e1953.
ALMEIDA LM, et al. Fatores associados ao sobrepeso e obesidade infantil. Revista Eletrônica Acervo Saúde, 2020; 58: e4406.
ANGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA (ANVISA). Avandia® (rosiglitazona): cancelamento do registro devido ao risco cardiovascular do medicamento. 2010. Disponível em: http://antigo.anvisa.gov.br/informacoes-tecnicas13?p_p_id=101_INSTANCE_WvKKx2fhdjM2&p_p_col_id=column-1&p_p_col_pos=1&p_p_col_count=2&_101_INSTANCE_WvKKx2fhdjM2_groupId=33868&_101_INSTANCE_WvKKx2fhdjM2_urlTitle=alerta-snvs-anvisa-nuvig-gfarm-n-04-de-29-de-setembro-de-2010&_101_INSTANCE_WvKKx2fhdjM2_struts_action=%2Fasset_publisher%2Fview_content&_101_INSTANCE_WvKKx2fhdjM2_assetEntryId=400778&_101_INSTANCE_WvKKx2fhdjM2_type=content#:~:text=O%20cancelamento%20de%20registro%20dos,probabilidade%20de%20ocorr%C3%AAncia%20de%20doen%C3%A7as. Acessado em: 29 de novembro de 2021.
ARMENO ML, et al. Evaluation of two dietary treatments in obese hyperinsulinemic adolescents. Journal of pediatric endocrinology & metabolism, 2011; 24(9-10): 715-722.
ATABEK ME, PIRGON O. Use of metformin in obese adolescents with hyperinsulinemia: A 6-month, randomized, double-blind, placebo-controlled clinical trial. Journal of pediatric endocrinology & metabolism, 2008; 21(4): 339-348.
BALAGOPAL P, et al. Lifestyle-only intervention attenuates the inflammatory state associated with obesity: a randomized controlled study in adolescents. The Journal of pediatrics, 2005; 146(3): 342-48.
CALI AMG, et al. Rosiglitazone improves glucose metabolism in obese adolescents with impaired glucose tolerance: A pilot study. Obesity, 2011; 19(1): 94-99.
CLARSON CL, et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine, 2009; 36(1): 141-146.
Cloridrato de Metformina [package insert]. São Paulo: Torrent Pharmaceuticals Ltd; 2015.
COHEN J. Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit. Psychological Bulletin, 1968; 70(4), 213-220.
DORENBOS E, et al. Effect of a high protein/low glycaemic index diet on insulin resistance in adolescents with overweight/obesity - A PREVIEW randomized clinical trial. Pediatric obesity, 2020; 16(1): e12702.
EVIA-VISCARRA ML, et al. The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial. Journal of pediatric endocrinology & metabolism, 2012; 25(1-2): 41-49.
FRANKS PW, et al. Childhood predictors of young—onset type 2 diabetes. Diabetes, 2007; 56(12): 2964-2972.
GALVÃO TF, et al. Principais itens para relatar Revisões sistemáticas e Meta-análises: A recomendação PRISMA. Epidemiologia e Serviços de Saúde, 2015; 24(2): 335-342.
GARNETT SP, et al. Optimal macronutrient content of the diet for adolescents with prediabetes; RESIST a randomised control trial. The Journal of clinical endocrinology and metabolism, 2013; 98(5): 2116-2125.
GOMES JGF, et al. Exercício físico e redução da resistência à insulina em indivíduos portadores de Diabetes Mellitus tipo 2: uma revisão bibliográfica. Research, Society and Development, 2020; 9(7): 1-13.
JUÁREZ-LÓPEZ C, et al. Omega-3 polyunsaturated fatty acids reduce insulin resistance and triglycerides in obese children and adolescents. Pediatric diabetes, 2013; 14(5): 377-383.KANG HS, et al. Physical training improves insulin resistance syndrome markers in obese adolescents. Med Sci Sports Exerc, 2002;34(12):1920-27.
KANG HS, et al. Physical training improves insulin resistance syndrome markers in obese adolescents. Medicine and science in sports and exercise, 2002; 34(12): 1920-1927.
KIM J, et al. The effects of a 12-week jump rope exercise program on body composition, insulin sensitivity, and academic self-efficacy in obese adolescent girls. Journal of pediatric endocrinology & metabolism, 2020; 33(1): 129-137.
LETRO CB, et al. Õmega-3 e doenças cardiovasculares: uma revisão à luz das atuais recomendações. Revista Eletrônica Acervo Científico, 2021; 26: e7398.
LI W, et al. Clinical efficacy of metformin combined with lifestyle intervention for treatment of childhood obesity with hyperinsulinemia. International Journal of Clinical and Experimental Medicine, 2019;12(6): 7644-7650.
LOPES AB, et al. Aspectos gerais sobre a obesidade infantil: uma revisão narrativa. Revista Eletrônica Acervo Cientifico, 2021; 37: e8993.
LÓPEZ-ALARCÓN M, et. Supplementation of n3 long-chain polyunsaturated fatty acid synergistically decreases insulin resistance with weight loss of obese prepubertal and pubertal children. Archives of medical research, 2011; 42(6): 502-508.
LOVE-OSBORNE K, et al. Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. The Journal of pediatrics, 2008; 152(6): 817-822.
MCCORMACK SE, et al. Effects of exercise and lifestyle modification on fitness, insulin resistance, skeletal muscle oxidative phosphorylation and intramyocellular lipid content in obese children and adolescents. Pediatric obesity, 2014; 9(4): 281-291.
MINISTÉRIO DA SAÚDE. Diretrizes metodológicas: elaboração de revisão sistemática e metanálise de ensaios clínicos randomizados, 1 ed. Brasília: Editora do Ministério da Saúde, 2012; 92 p.
MINISTÉRIO DA SAÚDE. Obesidade infantil afeta 3,1 milhões de crianças menores de 10 anos no Brasil. 2021. Disponível em: https://www.gov.br/saude/pt-br/assuntos/noticias/obesidade-infantil-afeta-3-1-milhoes-de-criancas-menores-de-10-anos-no-brasil#:~:text=A%20estimativa%20%C3%A9%20que%206,preocupantes%20ao%20longo%20da%20vida. Acessado em: 10 de novembro de 2021.
NADEAU KJ, et al. Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. Pediatric diabetes, 2009; 10(1): 5-13.
OLIVEIRA VP, et al.. Reflexões sobre a relação entre resistência a insulina, diabetes mellitus e obesidade na adolescência à luz da literatura. Revista Eletrônica Acervo Saúde, 2020; 41: e2105.
ORGANIZAÇÃO PANAMERICANA DE SAÚDE. 2022. Dia Mundial da Obesidade 2022: acelerar ação para acabar com a obesidade. Disponível em: https://www.paho.org/pt/noticias/4-3-2022-dia-mundial-da-obesidade-2022-acelerar-acao-para-acabar-com-obesidade. Acessado em: 13 de setembro de 2022.
SBD. Diretrizes da Sociedade Brasileira de Diabetes 2019-2020. São Paulo: Clannad Editora Científica, 2019; 489 p.
SBP. Obesidade na Infância e na Adolescência: Manual de Orientação. 3 ed. São Paulo: Sociedade Brasileira de Pediatria, 2019; 236p.
SCHULZ KF, et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. The BMJ, 2010; 340: c332.
SPSP. Enfrentando a Obesidade Infantil. Atualize-se, 2019; 4(2): 5-14.
TEIXEIRA RC. Metformina: revisão dos usos clínicos e potencial para tratamento da Pré-eclampsia. Trabalho de Conclusão de Curso( Especialista em Farmacologia)- Universidade Federal de Minas Gerais, Belo Horizonte, 2020; 56p.
UNICEF, WHO, IBRD. Levels and trends in child malnutrition: Key Findings of the 2020 Edition of the Joint Child Malnutrition Estimates. World Health Organization, 2020; 1-15.
VAN DER AA MP, et al. Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial. Nutrition & diabetes, 2016; 6(8): e228.
VIGITEL BRASIL 2021. ESTIMATIVAS SOBRE FREQUÊNCIA E DISTRIBUIÇÃO SOCIODEMOGRÁFICA DE FATORES DE RISCO E PROTEÇÃO PARA DOENÇAS CRÔNICAS NAS CAPITAIS DOS 26 ESTADOS BRASILEIROS E NO DISTRITO FEDERAL EM 2021. 1 ed. Brasília: Ministério da Saúde, 2022; 128p.
WIEGAND S, et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin-resistant adolescents: a prospective, placebo-controlled, randomized study. European journal of endocrinology, 2010; 163(4): 585-592.
YANOVSKI JA, et al. Effects of metformin on body weight and body composition in obese insulin-resistant children: A randomized clinical trial. Diabetes, 2011; 60(2): 477-485.